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T cells must selectively target epitopes, which are functionally
conserved (present in the majority of currently circulating
and reactivated HIV-1 strains) and, at the same time, beneﬁcial
(responses to which are associated with better clinical status
and control of HIV-1 replication), and rapidly reach protective
frequencies upon exposure to the virus. Heterologous prime-
boost regimens using virally vectored vaccines are currently
the most promising vaccine strategies; nevertheless, induction
of robust long-term memory remains challenging. To this
end, lentiviral vectors induce high frequencies of memory cells
due to their low-inﬂammatory nature, while typically inducing
only low anti-vector immune responses. Here, we describe con-
struction of novel candidate vaccines ZVex.tHIVconsv1 and
ZVex.tHIVconsv2, which are based on an integration-deﬁcient
lentiviral vector platform with preferential transduction of hu-
man dendritic cells and express a bivalent mosaic of conserved-
region T cell immunogens with a high global HIV-1 match.
Each of the two mosaic vaccines was individually immuno-
genic. When administered together in heterologous prime-
boost regimens with chimpanzee adenovirus and/or poxvirus
modiﬁed vaccinia virus Ankara (MVA) vaccines to BALB/c
and outbred CD1-Swiss mice, they induced a median frequency
of over 6,000 T cells/106 splenocytes, which were plurifunc-
tional, broadly speciﬁc, and cross-reactive. These results sup-
port further development of this vaccine concept.Received 22 June 2016; accepted 1 December 2016;
http://dx.doi.org/10.1016/j.ymthe.2016.12.004.
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Vaccine protection against infection/disease requires targeting the
causative microorganisms at their most vulnerable sites by robust
and timely immune responses.1,2 Robustness broadly sums the overall
magnitude of responses and effectiveness of their protective func-
tions, which have to be exerted at the right anatomical localization
at the right time.3,4 To blunt immune attacks, highly variable micro-
organisms evolved multiple evasive strategies, of which perhaps the
most common employs so-called decoy epitopes.5,6 These are easily
accessible, highly immunogenic determinants that do not stop themi-
crobes when targeted. This is because themost exposed decoy sites are494 Molecular Therapy Vol. 25 No 2 February 2017 ª 2017 The Authors.
This is an open access article under the CC BY license (http://creativecin protein regions non-essential for survival, structure, or function
and are, therefore, easily mutated to render the mounted responses
ineffective.7–9 In contrast, structurally and functionally important re-
gions are frequently subdominant.7–13 This is equally true for anti-
body and cytotoxic T lymphocyte (CTL) responses.
Natural infection by HIV type 1 (HIV-1) induces strong T cell re-
sponses; however, they fail to protect against progression to AIDS
due to continued immune escape.8,14–19 Thus, effective vaccines
should direct T cells to the functionally and structurally conserved re-
gions of HIV-1 proteins.20–24 Although these regions often contain
subdominant epitopes, these are less prone to immune escape due
to a resulting loss of replicative ﬁtness.25–29 Such regions are common
to most HIV-1 variants including transmitted/founder viruses offer-
ing the potential for deployment against diverse worldwide circu-
lating strains as well as already escaped viruses reactivated from
the latent reservoirs.27 We have pioneered virally vectored T cell vac-
cines designed as conserved alternating-clade consensus sequences
(HIVconsv, ﬁrst generation)23 and taken them into clinical evaluation
as heterologous prime-boost regimens.30–33 More recently, we
enhanced this conserved-region approach by replacing the consensus
sequences with a bivalent mosaic design (tHIVconsvX, second gener-
ation),34 which computationally increases as much as possible the
match of candidate vaccines to the currently worldwide circulating
HIV-1 variants for maximum effector efﬁcacy.34–38 Furthermore,
we adjusted the boundaries of conserved regions to cover the majority
of conserved and, at the same time, beneﬁcial CTL epitopes, which
have been associated in HIV-1-positive, treatment-naive cohorts on
four continents with low viral load and high CD4+ T cell count.34,39,40
Finally, each of the six tHIVconsvX immunogens tHIVconsv1–
tHIVconsv6 has the six conserved regions organized in a unique orderommons.org/licenses/by/4.0/).
www.moleculartherapy.orgto minimize induction of T cell responses to junctions, which are not
present in the HIV-1 proteome and are, therefore, an avoidable
distraction to the immune response.34
Initially, the tHIVconsvX conserved mosaic immunogens were
administered by a combination of non-replicating simian (chim-
panzee) adenovirus and non-replicating modiﬁed vaccinia virus An-
kara (MVA) vectors with or without plasmid DNA priming. We have
demonstrated high immunogenicity of these heterologous prime-
boost regimens in both healthy and HIV-1-positive adults.31,33 Both
adenoviruses and poxviruses prime T cells in a high-inﬂammatory
environment, which results in a brisk expansion of polyfunctional
effector T cells, but may lead to suboptimal induction of boostable
central memory T cell populations, which are important for long-
term protection.41 Furthermore, heterologous prime-boost regimens
using a low-inﬂammatory prime, such as DNA and dendritic cell
(DC)-based vaccination, followed by a high-inﬂammatory boost
induced superior memory T cell responses.41 Thus, lentiviral vectors
are attractive vaccine modalities for induction of robust T cell re-
sponses against infectious disease and cancer.42–44 We evaluated a
novel third-generation lentiviral vector designated ZVex, which selec-
tively targets DCs via interaction of its Sindbis-virus-derived envelope
protein with the receptor DC-speciﬁc intercellular adhesion molecule
(ICAM)-3 grabbing non-integrin DC-SIGN (CD209) expressed on
immature DCs and is currently being advanced in cancer immuno-
therapy trials. ZVex is an HIV-1-derived, self-inactivating vector
with the additional safety feature of integration deﬁciency, which is
achieved by the combination of integrase inactivation and extended
30 deletion of the vector backbone.45,46
In the presentwork, ZVex-vectored vaccines expressing a complement-
ing pair of tHIVconsvX bivalent conservedmosaic immunogens desig-
nated ZVex.tHIVconsv1 and ZVex.tHIVconsv2 demonstrated high
T cell immunogenicity alone and in heterologous prime-boost regi-
mens with vaccines ChAdOx1.tHIVconsv5+ChAdOx1.tHIVconsv6
vectored by engineered chimpanzee adenovirus Y25 and
MVA.tHIVconsv3+MVA.tHIVconsv4.34 Taken together, these results
support development of a heterologous prime-boost regimen using
ZVex- and ChAdOx1- and/or MVA-vectored vaccines expressing
conserved HIV-1 T cell epitopes for clinical application.
RESULTS
Design and Construction of the ZVex.tHIVconsv1 and
ZVex.tHIVconsv2 Vaccines
Design of the six bivalent conserved mosaic tHIVconsvX immuno-
gens of 872 amino acids (Figure 1A) was described previously.34,47
For vaccinations, the mosaic pairs are administered together
as tHIVconsv1+tHIVconsv2, tHIVconsv3+tHIVconsv4, and
tHIVconsv5+tHIVconsv6. Note that in each immunogen, the indi-
vidual regions are in different orders to avoid possible induction
of strong, but irrelevant, responses to potential junctional epitopes.
The integration-deﬁcient lentivector platform ZVex was described
previously.46 The open reading frames coding for conserved immu-nogens tHIVconsv1 and tHIVconsv2 (Figure 1A) were ﬁrst individu-
ally inserted into the transfer vector genome and novel vaccines
ZVex.tHIVconsv1 and ZVex.tHIVconsv2 were then prepared by a
co-transfection of ﬁve distinct plasmid DNAs: the transgene-coding
lentivector genome, the modiﬁed Gag/Pol packaging plasmid, two
separate plasmids expressing the accessory proteins Rev of HIV-1
and Vpx of SIVmac, and a plasmid expressing a modiﬁed Sindbis vi-
rus glycoprotein.
Themosaic pairs of vaccines were delivered by heterologous regimens
combining lentivirus vectors, simian adenovirus, and poxvirus MVA
(Figure 1B). Sequential administrations of heterologous vectors avoid
buildup of anti-vector immunity, which dampens induction of CTLs
against the transgene products.48–50
ZVex.tHIVconsv1 and ZVex.tHIVconsv2 Vaccines Are
Immunogenic in Mice
The initial conﬁrmation of immunogenicity of each of the con-
structed vaccine components separately was carried out in mice.
Elicited HIV-1-speciﬁc T cells were measured in an interferon
(IFN)-g enzyme-linked immunospot (ELISPOT) assay.34 Mosaic
proteins differ in about 10% of amino acids and the 401 unique
15-mer peptides overlapping by 11 amino acids (15/11) derived
from both mosaics 1 and 2 were assembled into 10 peptide pools
P1–P10, in which paired variant peptides were always in the same
pool; this allowed us to sum the individual pool frequencies of re-
sponding cells to calculate total magnitudes of the response for
each animal.34
Increasing doses of the individual ZVex.tHIVconsv1 and ZVex.
tHIVconsv2 vaccines ranging from 5  108 to 1  1010 genome
copies (gc) per dose (Table S1) were administered to the BALB/c
mice. The gc-to-infectious unit ratio is consistently between 10:1
and 30:1. Our previous results in the H-2d haplotype indicated that
peptide pools P1 and P4 contained the most dominant epitopes de-
tecting approximately 87% of the total response;34 therefore, for
simplicity, only the P1 and P4 pools were used in most immunologic
readouts. Thus, single administrations of ZVex.tHIVconsv1 and
ZVex.tHIVconsv2 induced speciﬁc T cell frequencies with medians
of 570 and 193 spot-forming units (SFU)/106 splenocytes for P1
and exceeding 1,200 and 163 SFU/106 splenocytes for P4, respec-
tively, at the intermediate dose of 5  109 gc (Figure 2). This dose
was chosen as the total dose for further experiments.
T Cell Induction by ZVex Vaccines Is Augmented by
Heterologous Boost
Induction of T cells against the conserved HIV-1 regions was as-
sessed in homologous ZVex-ZVex and heterologous ZVex-MVA
and ZVex-ChAdOx1 regimens (note that each ZVex, MVA, and
ChAdOx1 administration delivers two mosaic vaccines each; see
Figure 1B and Table S1). While the IFN-g ELISPOT assay indi-
cated high T cell frequencies induced by the homologous ZVex-
ZVex regimen with medians of 775 and 1,675 SFU/106 splenocytes
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(A) tHIVconsvX immunogens (insets). The vaccines focus
T cells on six highly functionally conserved regions
of HIV-1 Gag and Pol proteins and their efficacy is
enhanced by maximizing the vaccine match to global
HIV-1 isolates through a computer-designed bivalent
mosaic47 and inclusion of beneficial epitopes.39,40 For
each immunogen tHIVconsv1-tHIVconsv6, the selected
conserved regions are organized in different orders to
avoid boosting of potential junctional epitopes. Mosaic 1
and mosaic 2 are always used together for each
administrated dosing. (B) The six vaccine components
used in this work: tHIVconsv1 and tHIVconsv2 are
delivered by integration-deficient lentivirus vector ZVex,
tHIVconsv3 and tHIVconsv4 are delivered by non-repli-
cating poxvirus MVA, and tHIVconsv5 and tHIVconsv6
are delivered by non-replicating simian (chimpanzee)
adenovirus ChAdOx1.
Molecular Therapycombination with heterologous MVA and ChAdOx1 boosts for
both regimens reached similar median frequencies of 1,525 and
5,500 SFU/106 splenocytes for the two respective P1 and P4 pools
(Figure 3A). Thus, priming with ZVex and boosting with poxvirus
MVA or simian adenovirus ChAdOx1 strongly enhanced T cell re-
sponses to conserved regions.
Plurifunctionality of the vaccine-elicited CD8+ T cells in terms of
IFN-g, tumor necrosis factor (TNF)-a, and interleukin (IL)-2 pro-
duction and degranulation, the equivalent of killing measured by sur-
face expression of CD107a, was assessed using a polychromatic ﬂow
cytometry. The relative inter-regimen percentages of speciﬁc T cells
correlated well with the IFN-g ELISPOT assay. For the strongest pep-
tide pool P4, the T cell frequencies detected for the ZVex-MVA
regimen reached medians of 13.4%, 12.1%, 1.2%, and 13.0% respond-496 Molecular Therapy Vol. 25 No 2 February 2017ing cells of the total CD8+ T cells in the spleen
for IFN-g, TNF-a, IL-2, and CD107a, respec-
tively (Figure 3B). Responses to pool P1 were
less than one-third of those to P4. The heterolo-
gous prime-boost regimens again induced the
highest plurifunctional responses (Figure 3C).
Conserved Mosaic-Induced T Cells
Recognize Variant HIV-1 Peptides
Next, we tested comprehensively heterologous
vaccine regimens and used the generated
T cell responses to assess the “depth” of recog-
nition of epitope variants induced by the
bivalent mosaic immunogens. First, we tested
ﬁve regimens involving lentivirus vectors
ZVex-ZVex, ZVex-MVA, ZVex-ChAdOx1,
ChAdOx1-ZVex, and MVA-ZVex and
compared their immunogenicity with that of
our currently clinically pursued ChAdOx1-
MVA combination. Thus, using the immuno-dominant peptide pool P4 in the IFN-g ELISPOT assay, the two
strongest and statistically inseparable from each other were the
ZVex-MVA and ChAdOx1-MVA regimens; frequencies detected
by pool P1 were lower than those to P4 and similar among regimens
(Figure 4A). The overall trend of the regimens’ relative hierarchy for
induction of IFN-g was reproduced by the intracellular cytokine
staining analysis (Figure 4B). Using all 10 pools P1–P10 covering
15/11 peptides across the six conserved regions of the two mosaic
immunogens, we also demonstrated the role of the ZVex-vectored
vaccines in priming responses for ChAdOx1 and MVA, which was
most obvious for the immunodominant pool P4 (Figure 4C). This
experiment also indicated that the homologous empty vector
ZVex-ZVex regimen induced responses to conserved HIV-1 Gag
pools P1 and to a lesser extent P2, with median 613 and 72 SFU/
106 splenocytes, respectively (Figure 4C).
Figure 2. Dose Response for ZVex.tHIVconsv1 and
ZVex.tHIVconsv2
Groups of BALB/c mice were immunized with increasing
doses of either ZVex.tHIVconsv1 or ZVex.tHIVconsv2
vaccine alone administered intramuscularly (Table S1).
Immune splenocytes were tested in an IFN-g ELISPOT
assay unstimulated (Un) or stimulated with peptide pools
P1 or P4. Frequencies of conserved-region-specific
T cells are shown as the median and interquartile range
(n = 4).
www.moleculartherapy.orgTo assess the potential for cross-recognition of diverse HIV-1 isolates
following the bivalent mosaic immunization, we examined the
tHIVconsv1+HIVconsv2-elicited major histocompatibility complex
(MHC) class I-restricted responses to epitopes AMQ (AMQMLKETI;
pool P1) and VLV (VLVGPTPVNI; pool P4), which are on the top of
the CD8+ T cell H-2d-restricted hierarchy of the conserved mosaic re-
gions.34 For each epitope, we used the peptide pool, the two most
stimulatory 15-mer peptides in the pool encompassing the minimal
epitope, as well as four minimal peptide variants found in natural
HIV-1 isolates present in the Los Alamos National Laboratory HIV
Sequences Database (LANL-HSD). Overall, regimens did not inﬂu-
ence the relative SFU among tested variant peptides and the overall
pool SFU magnitudes were reﬂected by the relative magnitudes of in-
dividual peptide responses (Figure 4D). The minimal index peptides
tended to yield higher frequencies compared to their parental 15-mer
peptides, which require processing prior to MHC binding, and their
other subdominant variants. Thus, for the weakest AMQ of the two
epitopes, three of four tested minimum peptide variants were recog-
nized and peptide variant AMELFLKDTA was not recognized at all.
For the strongest VLV epitope of pool P4, four of four variants were
recognized. Thus, the recognition of mutated epitopes induced by the
bivalent mosaic extended beyond the two variants present in the
tHIVconsv1 and tHIVconsv2 immunogens.
ZVex-Vectored Vaccines Induce Robust and Broadly Specific
T Cells in Outbred Animals
Measurements of speciﬁc T cells have been aided by the use of
isogenic mouse strains, which greatly simplify the immunologic read-
outs and decrease the inter-animal variation and hence animal
numbers. However, an outbred mouse stock provides more rigorous
and realistic tests for vaccine immunogenicity. For these reasons, we
used outbred mouse stock CD1-Swiss for comparison of the ZVex-
MVA, ChAdOx1-MVA, and ZVex-ChAdOx1-MVA regimens. In
this experiment, we enumerated the vaccine-elicited T cells in an
IFN-g ELISPOT assay again using all 10 pools P1–P10. Overall, the
vaccination induced broadly speciﬁc T cells with a median (range)
of 6 (4–6), 3 (0–7), and 6 (2–8) of recognized peptide pools with
T cell frequencies above 50 SFU/106 splenocytes for the ZVex-
MVA, ChAdOx1-MVA, and ZVex-ChAdOx1-MVA regimens,
respectively (Figure 5). The total magnitudes reached a median
(range) of 6,280 (450–8,320), 3,730 (0–8,600), and 6,040 (170–
16,120), respectively, which were statistically indistinguishable. These
results suggest a good range of responsiveness in outbred animals andsupport further development of the ZVex.tHIVconsv1 and ZVex.
tHIVconsv2 vaccines toward clinical use.
DISCUSSION
In the present work, we describe construction of two novel compo-
nents of a candidate anti-HIV-1 T cell-based vaccine used together
in a heterologous prime-boost regimen. The design combines
conserved-region bivalent mosaic T cell immunogens with a uniquely
high match to global HIV-1 isolates34 and the novel integration-deﬁ-
cient lentivirus vector ZVex, which combines multiple safety features,
including integration deﬁciency, with efﬁcient targeting and trans-
duction of human dendritic cells.46 The two novel vaccines ZVex.
tHIVconsv1 and ZVex.tHIVconsv2 induced robust, variant cross-
reactive, and plurifunctional T cell responses, which were broadly
speciﬁc in outbred mice. The potency of the ZVex-MVA regimen
for CD8+ T cell induction was as good as that of the currently pursued
ChAdOx1-MVA. These attributes meet many desired features of
candidate HIV-1 vaccines, which should progress to clinical
evaluation.
The bivalent mosaic design of HIV-1 T cell vaccines represents the
second generation of conserved immunogens34 and follows the ﬁrst
generation of alternating-clade consensus sequences.31 The second-
generation immunogens combine the three currently most advanced
approaches for T cell vaccines to tackle HIV-1 diversity and escape,
whereby the efﬁcacy of refocused CD8+ T cells on the structurally
and functionally constrained regions of HIV-1 proteins (mutations
that result in ﬁtness loss25–28) is further enhanced by the currently
superior vaccine match to global HIV-1 variants of the bivalent
mosaic34,35,47 and inclusion of beneﬁcial T cell epitopes.34,39,40
Here, we demonstrated that these conserved mosaic immunogens
can be efﬁciently presented to the murine immune system by the
ZVex platform, which was highly immunogenic on its own and com-
bined well with the ChAdOx1- andMVA-vectored vaccines currently
lined up for clinical evaluation. Elicited T cells recognized several var-
iants of the two investigated epitopes, including those not present in
the immunogens.
The traditional vaccine approach of live attenuation is currently
not considered safe for HIV-1, and subunit vaccines have to date
not induced sufﬁcient protection as stand-alone modalities, despite
the use of novel adjuvants.51–53 Thus, non-replicating viral vectors
including derivatives of human and simian adenoviruses andMolecular Therapy Vol. 25 No 2 February 2017 497
AB
C
Figure 3. Functionality of HIV-1-Specific CD8+ T Cells
Induced by Prime-Boost Regimens
Groups of BALB/c mice were immunized using prime-
boost regimens of ZVex, MVA, and ChAdOx1 (note that
each vaccine modality delivered both mosaic 1 andmosaic
2 together; see Table S1) and were euthanized 9 days later.
Vaccine-elicited T cells were enumerated in an (A) IFN-g
ELISPOT assay or (B) intracellular cytokine staining assay
determining the fractions of cells producing intercellular
signaling molecules IFN-g, TNF-a, and IL-2 and de-
granulating (CD107a) upon restimulation with peptide
pools P1 or P4. See Figure S1 for the gating strategy.
Specific T cell frequencies are shown as the median and
interquartile range (n = 4). The Kruskal-Wallis test (ANOVA)
was used for each peptide pool to determine the approx-
imate P values shown above the graph followed by multiple
comparisons of vaccine groups Z-Z versus Z-M, Z-Z
versus Z-C, and Z-M versus Z-C corrected by the
Dunn test. As none of the differences between Z-M versus
Z-C were significant, asterisks indicate significance in the
first two comparisons (*p < 0.05; **p < 0.01). (C)
The pie charts indicate the plurifunctionality of vaccine-
elicited tHIVconsvX-specific T cells: yellow, one function;
green, two functions; blue, three functions; and red, four
functions.
Molecular Therapypoxviruses, as well as DNA, alphavirus replicons, adeno-associated
viruses, and others are being studied because of their capacity to
induce integrated immune responses consisting of antibody and
T cells, which, when effective, are believed to be critical for prevention
and control of HIV-1 infection.21,22,54,55 Since repeated vaccination
with homologous vector induces strong anti-vector immunity, which
blunts responses against the transgene product, prime-boost regi-
mens with heterologous vectors are generally viewed as supe-
rior.21,56–58 In the past years, lentiviral vectors have increasingly
been explored as vaccine platforms for cancer and infectious diseases
because of their capability to transduce non-dividing antigen-pre-498 Molecular Therapy Vol. 25 No 2 February 2017senting cells, directly prime CD8+ T cells, and
induce robust T cell memory responses due
to their low-inﬂammatory mode of action
and prolonged low-level antigen production.43
Lentivirus-based vaccines expressing structural
and non-structural HIV-1 proteins induced
robust immune responses in preclinical animal
models and partially protected non-human pri-
mates against simian immunodeﬁciency virus
(SIV) challenge.59 In addition, heterologous im-
munization with a lentiviral vaccine and human
adenovirus vector HAdV-5 expressing HIV-1
Gag, Pol, and Rev proteins resulted in superior
immunogenicity and overcame pre-existing
anti-HAdV-5 immunity.60 While the majority
of these experiments were performed with inte-
grating lentiviral vectors pseudotyped with the
envelope glycoprotein of vesicular stomatitisvirus VSV-G, giving these vectors a broad tropism, recent develop-
ments have explored integration deﬁciency as an important safety
feature and targeting of antigen-presenting cells as a means to modu-
late immune responses.61,62
ZVex is a third-generation lentiviral vector targeted to professional
antigen-presenting cells through the selective interaction of an engi-
neered Sindbis virus envelope with DC-SIGN expressed on immature
DCs.63 To overcome the SAMHD-1-mediated resistance of human
dendritic cells to lentivirus infection, the accessory protein SIVmac
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Figure 5. Broad Specificity of tHIVconsvX-Elicited T Cells for Conserved Epitopes
Groups of seven outbred CD1-Swissmice were immunized using the ZVex-MVA, ChAdOx1-MVA, or ZVex-ChAdOx1-MVA regimens (note that each vaccinemodality delivered
bothmosaic 1 andmosaic 2 together: see Table S1) andwere euthanized 1week later. Isolated splenocytes from individual micewere tested in an IFN-g ELISPOT assay against
10 pools P1–P10 of 15/11 peptides across the full length of all six tHIVconsvX conserved regions. Average frequencies of triplicate wells are shown for each mouse and pool.
Numbers above each animal composite column give the number of peptide pools recognized by vaccine-elicited T cells with frequencies above 50 SFU/106 splenocytes.
Molecular TherapyIntegration deﬁciency of ZVex was achieved through genetic inactiva-
tion of the integrase (D64Vmutation) and extended deletion of the 30
region of the vector genome.45,46 In mice, ZVex induced robust
polyfunctional effector and memory CD8+ T cell responses with pro-
phylactic and therapeutic effects in infectious disease and tumor
challenge models after single injection.45,65 ZVex is currently being
evaluated in phase 1 and 2 cancer therapy studies in humans.
Taken together, our data support further development of a conserved
mosaic HIV-1 immunogen-based strategy, utilizing heterologous
prime-boost approaches with the DC-targeted, integration-deﬁcient
lentiviral vector platform ZVex and MVA and/or ChAdOx1 vectors.
For the tHIVconsvX as well as other immunogens, we envisage a panel
of vectors delivering the same transgene,whichwill allowapersonalized
delivery avoiding known pre-existing anti-vector immunity, multiple
heterologous boosts for low responders, a maintenance of protective
levels of immunity over a prolonged period of time, andmore ﬂexibility
for combining future effectiveT andBcell vaccines into one regimen for
the bestHIV-1 control. Themultiple safety features of the ZVex vaccine
delivery technology and its T cell immunogenicitymake the ZVex plat-
form a very suitable member of such a vector panel for use in both the
HIV-1-negative healthy population as part of prevention strategies and
in HIV-1-positive patients for HIV-1 cure. For the best preventive im-
munization, vaccines inducing effectiveT cells will have to be combined
with those eliciting broadly neutralizing antibodies.66
MATERIALS AND METHODS
Synthetic Genes for tHIVconsv1 and tHIVconsv2
DNA fragments carrying the tHIVconsv1 and tHIVconsv2 open
reading frames were synthesized (Life Technologies) using human-Figure 4. Cross-Recognition of Epitope Variants following Prime-Boost Vaccin
Groups of BALB/c mice received vaccines vectored by ZVex (Z), MVA (M), and ChAdOx1
or empty ZVex without any transgene (Ze) in prime-boost regimens (Table S1) and were e
pools P1 or P4 indicated abovewere determined in IFN-g ELISPOT (A andC) and intrace
peptide pool to determine the approximate p values shown above the graph, followed by
asterisk indicates p < 0.05. (C) Mice were immunized using regimens involving only C or M
against all tHIVconsvX-derived peptide pools P1-P10 in an IFN-g ELISPOT assay. (D) Sp
pools P1 and P4, two 15-mer peptide variants as included in each of the pools, two optim
additional known variants present in the LANL-HSD. Results are presented as the med
500 Molecular Therapy Vol. 25 No 2 February 2017ized codons and were preceded by a consensus Kozak sequence at
6 nucleotides to maximize protein expression.34
Construction of ZVex.tHIVconsv1 and ZVex.tHIVconsv2
Lentiviral Vector Vaccines
Transfer vector genomes encoding tHIVconsv1 and tHIVconsv2
were constructed by PCR ampliﬁcation of DNA fragments carrying
the tHIVconsv synthetic genes using forward and reverse primers
that containing Age1 and EcoR1 restriction sites, respectively. ID-
LV was produced as described previously using the ZVex (also known
as VP02) platform.45,46,65 Brieﬂy, ZVex ID-LV was produced via tran-
sient transfection of 293T cells with ﬁve plasmids: (1) the transfer vec-
tor that encodes the ZVex genome and tHIVconsv1 or tHIVconsv2,
(2) a modiﬁed rev-independent gagpol transcript, (3) accessory pro-
tein Rev fromHIV-1, (4) accessory protein Vpx from SIVmac, and (5)
the SinVar1 (E1001) envelop glycoprotein modiﬁed variant derived
from Sindbis virus. Harvested vector supernatants were ﬁltered
(0.22 mm) and concentrated by centrifugation, followed by benzonase
digestion, centrifugation through a sucrose cushion, and resuspen-
sion in a formulation Tris-HCl buffer containing 50 mM L-arginine,
5% sucrose. Vector preparations were aliquoted and stored at 80C
until use.
Mice and Immunization Regimens
Six-week-old female BALB/c mice were purchased from Harlan Lab-
oratories and housed at the University of Oxford Functional Geno-
mics Facility. Groups of animals were immunized intramuscularly
as indicated in Table S1. In the combined regimens of mosaics 1
and 2, half a dose for each vaccine type was used injecting mosaic 1
and mosaic 2 into the left and right hind quadriceps, respectively.ations
(C) (note that each vaccinemodality delivered both mosaic 1 andmosaic 2 together)
uthanized 1 week later. Frequencies of splenocytes recognizing tHIVconsvX peptide
llular cytokine staining (B) assays. The Kruskal-Wallis test (ANOVA) was used for each
multiple comparisons of vaccine regimens with Z-Z corrected by the Dunn test. The
alone and ZVex without any HIV-1-derived insert and their splenocytes were tested
lenocytes from mice immunized as in (A) were also tested for recognition of peptide
al-length epitope peptides as present in the twomosaic immunogens, and their two
ian and interquartile range, whereby n = 5 in (A), (B), and (D) and n = 4 in (C).
www.moleculartherapy.orgMice were euthanized between 1 and 2 weeks after the last vaccina-
tion. All procedures and care were approved by the University of
Oxford local research ethics committee and conformed strictly
to the UK Home Ofﬁce Guidelines under the Animals (Scientiﬁc
Procedures) Act 1986. Experiments were conducted under Project
License 30/3387 held by T.H.
Peptides
Over 90% pure 15-mer peptides overlapping by 11 amino acids (15/
11) spanning the entire six conserved regions of the tHIVconsv1 and
tHIVconsv2 immunogens were used. A total of 401 peptides were
assembled into 10 pools P1–P10 of between 34 and 47 peptides
each in a way that variant peptides were always present in the same
pool. Individual peptides were dissolved in DMSO at a concentration
of 20 mg/ml and stored at 80C. Working stocks of 4 mg/ml were
prepared by diluting 20 mg/ml stocks with PBS. Peptides were used
in assays at a ﬁnal concentration of 1.5 mg/ml.
IFN-g ELISPOT Assay
The ELISPOT assay was performed using the Mouse IFN-g ELISPOT
kit (Mabtech) according to the manufacturer’s instructions. Immune
splenocytes were collected and tested separately from individual mice.
Spots were visualized using sequential applications of a biotin-conju-
gated secondary anti-IFN-g monoclonal antibody (mAb) (R4-6A2,
Rat IgG1), an alkaline phosphatase, and a chromogenic substrate
(Bio-Rad) and were counted using the AID ELISPOT Reader System
(Autoimmun Diagnostika).
Intracellular Cytokine Staining
Cytokine production by splenocytes from immunized mice was
assessed by intracellular cytokine staining as described previously.34
Brieﬂy, splenocytes were stimulated with tHIVconsvX-derived 15/
11 peptides assembled into 10 pools, P1–P10, for 90 min at 37C
and then for an additional 5 hr in the presence of brefeldin A (Golgi-
plug; BD Biosciences) to prevent cytokine secretion. Cells were sur-
face stained with anti-CD8-R-phycoerythrin (PE)-Cy5 red (eBio-
science) antibodies and LIVE/DEAD ﬁxable aqua dead cell stain
(Invitrogen) and then permeabilized and incubated with various
combinations of anti-IL-2-ﬂuorescein isothiocyanate (FITC), anti-
CD107a-PE, anti-TNF-a-antigen-presenting cell (APC), and anti-
IFN-g-V450 monoclonal antibodies (BioLegend). Samples were ac-
quired on an LSR II ﬂow cytometer (BD Biosciences) and data were
analyzed using FlowJo software (version 9.5.2; Tree Star). Plurifunc-
tionality was assessed using Simpliﬁed Presentation of Incredibly
Complex Evaluations (SPICE) software (National Institute of Allergy
and Infectious Diseases [NIAID]).
Statistical Analysis
Statistical analyses were performed using Graph Pad Prism software
(version 6). Responses were assumed to be non-Gaussian in distribu-
tion; thus, results are presented as medians (ranges). Multiple com-
parisons were performed using the Kruskal-Wallis test with the
Dunn multiple comparison post-test for non-parametric data. A
p value < 0.05 was considered signiﬁcant.SUPPLEMENTAL INFORMATION
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